INSPRA en es it fr

INSPRA Brand names, INSPRA Analogs

INSPRA Brand Names Mixture

  • No information avaliable

INSPRA Chemical_Formula

C24H30O6

INSPRA RX_link

http://www.rxlist.com/cgi/generic/inspra.htm

INSPRA fda sheet

INSPRA FDA

INSPRA msds (material safety sheet)

INSPRA Synthesis Reference

No information avaliable

INSPRA Molecular Weight

414.491 g/mol

INSPRA Melting Point

No information avaliable

INSPRA H2O Solubility

Slightly soluble

INSPRA State

Solid

INSPRA LogP

2.445

INSPRA Dosage Forms

Tablet (film-coated - 25, 50 mg)

INSPRA Indication

For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

INSPRA Pharmacology

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

INSPRA Absorption

The absolute bioavailability of eplerenone is unknown.

INSPRA side effects and Toxicity

The most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.

INSPRA Patient Information

INSPRA Organisms Affected

Humans and other mammals